2020
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. Journal Of Clinical Oncology 2020, 38: 1346-1366. PMID: 31928404, DOI: 10.1200/jco.19.02309.Peer-Reviewed Original ResearchConceptsProgesterone receptor testingBreast cancerEndocrine therapyReceptor testingExpert panelClinical practice guideline recommendationsMultidisciplinary international expert panelClinical Oncology/CollegeEndocrine therapy benefitPractice guideline recommendationsER-positive cancersBreast cancer guidelinesInvasive breast cancerFuture breast cancerBreast cancer samplesInternational expert panelReporting of casesPgR testingTumor cell nucleiCancer guidelinesGuideline recommendationsGuideline updateDuctal carcinomaER testingLow positives
2009
Evaluation of the false-negative rate of standardized and quantitative measurement of estrogen receptor (ER) in tissue using AQUA technology
Gustavson M, Welsh A, Jones C, Mayotte J, Tu J, Hopkins J, Rimm D, Christiansen J. Evaluation of the false-negative rate of standardized and quantitative measurement of estrogen receptor (ER) in tissue using AQUA technology. Journal Of Clinical Oncology 2009, 27: 567-567. DOI: 10.1200/jco.2009.27.15_suppl.567.Peer-Reviewed Original ResearchER protein expressionEstrogen receptorBreast cancer samplesPg/AQUA analysisFalse negative rateAQUA technologyCancer samplesAllred scoring systemProtein expressionChange of diagnosisEstrogen receptor testingReproducible diagnostic testFalse-negative testsHigh false-negative rateReceptor testingER testingAllred scoreLarge cohortNegative testAQUA scoreScoring systemMisclassified casesClinical settingConcordance rate